Fund moves
5 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 13, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 2, 2024 · Filed Nov 6, 2024
Novocure's Chief Operating Officer sold $734 of Novocure shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$734
Shares × reported transaction price
3 days after results of Oct 30, 2024, 72 days before results of Jan 13, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −6.1% | −0.4% | −5.7% |
| 30 days | +62.3% | +1.5% | +60.8% |
| 90 days | +37.0% | +1.4% | +35.5% |
| 180 days | −7.5% | −6.2% | −1.3% |
| 365 days | −38.1% | +12.7% | −50.8% |
Past results only. Not a forecast.
Fund moves
5 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 13, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Mukund Paravasthu (Chief Operating Officer) sold ~$2.5K of Novocure
Automatic saleFrank X Leonard (EVP, Pres., Novocure Oncology) sold ~$9.5K of Novocure
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.